Cirena, Inc.

Name

Cirena, Inc.

Legal name

Cirena, Inc.

Website

https://cirena.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Custom RNA Synthesis Services

NAICS

Chemical Manufacturing (325)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

Keywords

• Custom RNA synthesis
• Long oligonucleotide manufacturing
• Modified RNA oligos
• Nucleic acid chemistry services
• Phosphoramidite synthesis

Headquarters

HQ city

Boulder

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Custom RNA Oligo Synthesis: One-time transaction-based ordering of custom long RNA oligos (100-300nt) with various modifications. Customers provide sequence, quantity, and modification specifications. Pricing varies by length, quantity, and complexity. Free feasibility checks offered; paid synthesis for approved sequences.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Cirena provides custom solid-phase chemical synthesis of long, high-purity RNA oligonucleotides (100–300 nucleotides) for research and therapeutic applications. Orders are purified by liquid chromatography, verified by mass spectrometry, and shipped with QC data; production scales from microgram to gram quantities with a pathway to GMP manufacturing via CDMO partners.

Product overview

Cirena is a biotechnology company offering custom long RNA synthesis as a single unified service. Their core offering combines proprietary Long RNA Synthesis Technology (using 2′-O-Thionocarbamate nucleoside phosphoramidites capable of producing 100-300 nt RNA) with customizable RNA Modifications that include their proprietary PACE Modification backbone chemistry. All products undergo LC purification and MS verification. The company offers scalable production from microgram to gram scales with a pathway to GMP manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom RNA Oligo Synthesis Custom RNA oligo synthesis service delivering 100–300 nt oligonucleotides with site-specific chemical modifications, LC purification, and MS sequence-identity verification, ordered by sequence, quantity, and modification specifications and targeted at gene editing, RNA therapeutics, and structural biology researchers.
• PACE Backbone Modification A proprietary backbone chemistry option providing 1–2 orders of magnitude higher nuclease resistance than standard phosphorothioate modifications while preserving native-like duplex behavior, available on customer-requested oligos for gene editing and therapeutic RNA applications.

Quantifiable outcome

• 1-2 orders of magnitude higher intracellular stability vs. MS-modified counterparts over 24-96 hours
• +5 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CDMOs (Contract Development and Manufacturing Organizations)supportiveOthersCirena maintains close relationships with leading CDMOs (contract development and manufacturing organizations) to enable seamless scale-up to larger production volumes. The pathway to GMP manufacturing is described as straightforward through these partnerships.

Scale indicators3 records

Recent moves1 record

Expansion highlights4 records

Direct peers

• Integrated DNA Technologies (IDT): IDT is the largest independent custom oligonucleotide synthesis provider, offering extensive RNA oligo capabilities with broad modification catalogues. It is the most directly comparable competitor to Cirena in custom RNA synthesis, but at much greater scale and with a more generalist positioning across all oligo lengths.
• TriLink BioTechnologies: TriLink specializes in mRNA synthesis and modified nucleotides, with overlapping capabilities in custom RNA and modified oligos for therapeutic and research use. It is a direct peer in the chemically modified RNA space, particularly for therapeutic-grade production.
• Aldevron: Aldevron (now part of Danaher) manufactures nucleic acids including mRNA, plasmid DNA, and recombinant proteins for therapeutic developers. It is a direct peer in nucleic acid manufacturing, particularly relevant as Cirena's customers scale from research to clinical-grade production.
• Eurofins Genomics: Eurofins Genomics offers custom oligonucleotide synthesis with broad modification menus at industrial scale. It competes directly with Cirena on standard and modified RNA oligos for research customers.
• GenScript: GenScript provides custom oligo and gene synthesis services with global operations and a wide modification catalogue. It is a direct peer to Cirena in custom RNA for research and therapeutic applications, particularly for Asian and US biotech customers.
• LGC Biosearch Technologies: LGC Biosearch is a custom oligo synthesis provider with deep catalog of modifications and probe chemistry. It competes directly with Cirena in custom RNA for genomics, gene editing, and modified oligo workflows.

Emerging players

• Twist Bioscience: Twist applies silicon-based DNA synthesis to large-scale oligo pools and gene fragments. While its core is DNA, it represents an emerging platform approach to nucleic acid synthesis that could eventually compete with chemical synthesis providers like Cirena in adjacent applications.

Broad incumbents

• Merck KGaA / Sigma-Aldrich (Custom Oligos): Sigma-Aldrich / Merck offers custom oligonucleotide synthesis services and a deep catalogue of nucleic acid chemistry products. It competes broadly with Cirena in custom modified oligos for academic and industrial research.
• Thermo Fisher Scientific (GeneArt / Oligo / Custom RNA): Thermo Fisher's GeneArt and related custom RNA offerings serve gene synthesis, mRNA, and modified oligos through its life-sciences tools portfolio. It is a broad incumbent that overlaps Cirena's custom synthesis capabilities as part of a much larger instrumentation and reagents franchise.
• Agilent Technologies (Custom Oligos): Agilent offers custom oligonucleotide synthesis and a broad life-sciences analytical portfolio. It competes in the modified oligo and nucleic acid chemistry space as part of a wider analytical instruments and reagents business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cirena, Inc.